Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and High Dose IL-2 in Metastatic Melanoma
NCT03476174Phase 2Terminated
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in melanoma. Started May 2018; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03476174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03476174.